[Clinical experiences with polyethylene glycol-bound E. coli L-asparaginase in patients with multiple recurrences of acute lymphoblastic leukemia].
The efficiency and toxicity of E. coli-L-Asparaginase coupled to polyethyleneglycol (PEG-ASP) was investigated in 5 patients with second relapse of acute lymphoblastic leukemia. PEG-ASP was administered at a dose of 2000 U/m2 as infusion over 2 hrs. every 2 weeks. Following an initial single agent phase, PEG-ASP was combined with prednisone, vincristine, adriamycin and methotrexate i.t. Following induction, all 5 patients were in third remission. The remissions lasted from 3 to 9 months, median 4 months. The toxicity was transient and mild. Also in patients sensitized against native L-Asparaginase no anaphylactic reactions were observed.
Jürgens
H
H
Abt. für Hämatologie und Onkologie, Universität Düsseldorf.
Schwamborn
D
D
Körholz
D
D
Wahn
V
V
Göbel
U
U
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001215:Asparaginase / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use*; D011241:Prednisone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D011092:Polyethylene Glycols; D014750:Vincristine; C042705:pegaspargase; D004317:Doxorubicin; D001215:Asparaginase; D011241:Prednisone; D008727:Methotrexate
Klinische Erfahrungen mit polyäthylenglykol-gekoppelter E. coli-L-Asparaginase bei Patienten mit ALL-Mehrfachrezidiv.